Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Bio-Rad reports Q1 2023 growth amidst challenges and Russian sanctions impact

Bio-Rad's Q1 2023 showcased solid growth in core business amid challenges and opportunities. The impact of Russian sanctions on revenue and revised 2023 outlook were key points of discussion. The company's focus on cash deployment for M&A and strong demand in diagnostics and bioprocessing segments are notable.

Bio-Rad reports decline in Q2 sales, sees strength in ddPCR

Bio-Rad's Q2 2023 earnings call highlighted a decline in net sales, revised financial outlook, and challenges in the BioPharma segment. However, the company demonstrated strength in the Clinical Diagnostics Group and ddPCR performance, while maintaining discipline in expenses. Opportunities lie in the strong performance of ddPCR and potential share repurchases.

Bio-Rad reports Q3 sales decline but sees growth opportunities

Bio-Rad's Q3 2023 saw declining net sales, but reported net income improved significantly. The company faces challenges in various segments and anticipates a challenging market environment. However, it sees opportunities for growth in the Diagnostics group and plans to enter new segments in 2024.

Bio-Rad reports Q4 decline, eyes 2024 recovery with margin focus

Bio-Rad faced challenges in Q4 2023 with declining net sales, particularly in the Life Science Group, but saw growth in Clinical Diagnostics. The company aims for a recovery in 2024 through revenue growth and margin expansion strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity. F.

Bio-Rad Announces Life Science Group Management Changes

Arbor Realty Trust

ATN International

ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.

New Strong Sell Stocks for April 19th

The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.

Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-274-8461 within the U.S. or (+1) 203-518-9814 outside the U.S., acce.

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition

–     Bio-Rad expects to make equity investment in support of deal –     Agreement provides for global exclusivity in transplant monitoring commercialization –     Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 – Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a search for his successor. Dr. Last joined Bio-Rad in April of 2019 with.

Bio-Rad's Chief Operating Officer Andrew Last to Retire

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Off.

Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section o.

Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

Bio-Rad Laboratories, Inc. (BIO) Q4 2023 Earnings Call Transcript

Bio Rad Laboratories reported fourth-quarter profit that beat Wall Street estimates on Thursday, helped by a better-than-expected demand for its diagnostic instruments and quality control products offsetting weaker sales in its life-sciences unit.

Bio Rad Labs rises after posting upbeat fourth-quarter profit

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.10 per share, beating the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.31 per share a year ago.

Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.7 percent compared to the same per.

Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 888-259-6580 within the U.S. or +1 416-764-8624 outsid.

Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, President and CEO, and Andrew Last, Executive Vice President and COO, will host one-on-one meetings with investors during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, January 8 - 11, 2024. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developi.

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference

APA Corporation

Aptiv

First Solar

General Motors

Halliburton

Las Vegas Sands

Moderna

United Continental Hlds

Warner Bros Discovery Inc

Wall Street analysts forecast these names to deliver the biggest price gains in the S&P 500 over the next 12 months.

S&P 500 Stocks With the Most Upside

Bristol-Myers

Cigna

Humana

Incyte

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

6 Stock Picks in Healthcare for 2024

Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes

Caesars Entertainment

NVIDIA

Schlumberger

Wynn Resorts

Want to own the top S&P 500 stock of 2024? It's not going to be Nvidia again — and it won't even be in the top 10, analysts say.

Analysts Predict These Will Be Next Year's Top 10 Stocks

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Last - EVP and COO Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Jack Meehan - Nephron Tim Daley - Wells Fargo Conor McNamara - RBC Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

News for Bio-Rad Laboratories Stock (BIO)